TAZ and YAP are frequently activated oncoproteins in sarcomas

Colleen A. Fullenkamp, Sarah L. Hall, Omar I. Jaber, Brittany L. Pakalniskis, Erica C. Savage, Johanna M. Savage, Georgina K. Ofori-Amanfo, Allyn M. Lambertz, Stephanie D. Ivins, Christopher S. Stipp, Benjamin J. Miller, Mohammed M. Milhem, Munir R. Tanas

Research output: Contribution to journalArticlepeer-review


TAZ (WWTR1) and YAP are transcriptional coactivators and oncoproteins inhibited by the Hippo pathway. Herein we evaluate 159 sarcomas representing the most prevalent sarcoma types by immunohistochemistry for expression and activation (nuclear localization) of TAZ and YAP. We show that 50% of sarcomas demonstrate activation of YAP while 66% of sarcomas demonstrate activated TAZ. Differential activation of TAZ and YAP are identified in various sarcoma types. At an RNA level, expression of WWTR1 or YAP1 predicts overall survival in undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. Immunohistochemistry demonstrates that TAZ and YAP expression and activation are positively correlated with grade in the well-differentiated liposarcoma to dedifferentiated liposarcoma tumor progression sequence as well as conventional chondrosarcomas. TAZ and YAP are constitutively activated oncoproteins in sarcoma cell lines. Knock-down of TAZ and YAP demonstrate differential activity for the two proteins. Verteporfin decreases colony formation in soft agar as well as CTGF expression in sarcoma cell lines harboring activated TAZ and YAP.

Original languageEnglish (US)
Pages (from-to)30094-30108
Number of pages15
Issue number21
StatePublished - May 24 2016


  • Hippo pathway
  • Pathology Section
  • Sarcoma
  • TAZ
  • WWTR1
  • YAP

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'TAZ and YAP are frequently activated oncoproteins in sarcomas'. Together they form a unique fingerprint.

Cite this